Cargando…
Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
BACKGROUND: Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (w...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655990/ https://www.ncbi.nlm.nih.gov/pubmed/29070077 http://dx.doi.org/10.1186/s40199-017-0189-6 |
_version_ | 1783273645148209152 |
---|---|
author | Keshavarz, Khosro Lotfi, Farhad Sanati, Ehsan Salesi, Mahmood Hashemi-Meshkini, Amir Jafari, Mojtaba Mojahedian, Mohammad M. Najafi, Behzad Nikfar, Shekoufeh |
author_facet | Keshavarz, Khosro Lotfi, Farhad Sanati, Ehsan Salesi, Mahmood Hashemi-Meshkini, Amir Jafari, Mojtaba Mojahedian, Mohammad M. Najafi, Behzad Nikfar, Shekoufeh |
author_sort | Keshavarz, Khosro |
collection | PubMed |
description | BACKGROUND: Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes. METHODS: A systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as “linagliptin”, “type 2 diabetes mellitus”, “sitagliptin” and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta-analysis was used to conduct a systematic comparison between the two studied drugs. RESULTS: This network meta-analysis included 32 studies (Linagliptin vs PLB: n = 8, Sitagliptin vs PLB: n = 13, Linagliptin + MET vs PLB + MET: n = 4, and Sitagliptin + MET vs PLB + MET: n = 7) and a total of 13,747 patients. The results showed no significant difference between linagliptin and sitagliptin in terms of key efficacy and safety outcomes such as HbA1c changes from baseline, body weight change from baseline, percentage of patients achieving HbA1c <7, and percentage of patients experiencing hypoglycemic events (p > 0.05). The results showed that the efficacy of the two drug regimens was the same. CONCLUSIONS: Based on the results, there was no significant difference between the two drugs, i.e. linagliptin and sitagliptin, in terms of efficacy; in other words, the efficacy of the two drugs was the same. Therefore, the use of these two drugs depends on their availability and cost. GRAPHICAL ABSTRACT: Graphical abstract of the network meta-analysis performed to evaluate the alternatives under the study. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40199-017-0189-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5655990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56559902017-10-31 Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials Keshavarz, Khosro Lotfi, Farhad Sanati, Ehsan Salesi, Mahmood Hashemi-Meshkini, Amir Jafari, Mojtaba Mojahedian, Mohammad M. Najafi, Behzad Nikfar, Shekoufeh Daru Review Article BACKGROUND: Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes. METHODS: A systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as “linagliptin”, “type 2 diabetes mellitus”, “sitagliptin” and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta-analysis was used to conduct a systematic comparison between the two studied drugs. RESULTS: This network meta-analysis included 32 studies (Linagliptin vs PLB: n = 8, Sitagliptin vs PLB: n = 13, Linagliptin + MET vs PLB + MET: n = 4, and Sitagliptin + MET vs PLB + MET: n = 7) and a total of 13,747 patients. The results showed no significant difference between linagliptin and sitagliptin in terms of key efficacy and safety outcomes such as HbA1c changes from baseline, body weight change from baseline, percentage of patients achieving HbA1c <7, and percentage of patients experiencing hypoglycemic events (p > 0.05). The results showed that the efficacy of the two drug regimens was the same. CONCLUSIONS: Based on the results, there was no significant difference between the two drugs, i.e. linagliptin and sitagliptin, in terms of efficacy; in other words, the efficacy of the two drugs was the same. Therefore, the use of these two drugs depends on their availability and cost. GRAPHICAL ABSTRACT: Graphical abstract of the network meta-analysis performed to evaluate the alternatives under the study. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40199-017-0189-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-25 /pmc/articles/PMC5655990/ /pubmed/29070077 http://dx.doi.org/10.1186/s40199-017-0189-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Article Keshavarz, Khosro Lotfi, Farhad Sanati, Ehsan Salesi, Mahmood Hashemi-Meshkini, Amir Jafari, Mojtaba Mojahedian, Mohammad M. Najafi, Behzad Nikfar, Shekoufeh Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
title | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
title_full | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
title_fullStr | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
title_full_unstemmed | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
title_short | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
title_sort | linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655990/ https://www.ncbi.nlm.nih.gov/pubmed/29070077 http://dx.doi.org/10.1186/s40199-017-0189-6 |
work_keys_str_mv | AT keshavarzkhosro linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT lotfifarhad linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT sanatiehsan linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT salesimahmood linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT hashemimeshkiniamir linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT jafarimojtaba linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT mojahedianmohammadm linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT najafibehzad linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials AT nikfarshekoufeh linagliptinversussitagliptininpatientswithtype2diabetesmellitusanetworkmetaanalysisofrandomizedclinicaltrials |